StreetInsider.com News Articles

Scienture adds 12.5 million covered lives for Arbli payor network

Thu, 18 Jun 2026 08:05:38 -0400

Scienture Holdings (NASDAQ: SCNX) announced it has secured additional payor coverage for its Arbli™ (losartan potassium oral suspension) product, adding approximately 12.5 million covered lives, according to a company press release. The expanded coverage includes Medicare Part D supplement plans as well as commercial and government-sponsored healthcare channels.

The company said it is also working to expand pharmacy participation, relationships with pharmacy buying groups, specialty technology partnerships, and distribution capabilities. Scienture added that it is pursuing initiatives to increase Medicaid access for Arbli™.

"The addition of approximately 12.5 million covered lives, coupled with our growing pharmacy network, specialty technology relationships, and channel

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

Thu, 18 Jun 2026 08:05:00 -0400

Broader pharmacy access, channel expansion, and payer coverage position Arbli^™ for increased prescription volume and revenue growth

COMMACK, NY, June 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced significant progress in the commercialization of Arbli^™ (losartan potassium oral suspension), including expanded payor coverage, broader pharmacy access, new channel partnerships, and ongoing initiatives designed to increase

SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide

Thu, 18 Jun 2026 08:05:00 -0400

Broader pharmacy access, channel expansion, and payer coverage position Arbli^™ for increased prescription volume and revenue growth

SCIENTURE adds REZENOPY nasal spray to major health plan formulary

Tue, 09 Jun 2026 08:05:28 -0400

Scienture Holdings Inc. (NASDAQ: SCNX) announced that its REZENOPY naloxone nasal spray has been added to the formulary of a large national health plan, expanding coverage to over 100 million lives ahead of the product's planned mid-July commercial launch.

REZENOPY is a 10 mg naloxone nasal spray for emergency treatment of opioid overdose, which the company states is the highest FDA-approved naloxone dose per nasal spray available in the United States. The product received FDA approval in April 2024.

The company has secured Group Purchasing Organization agreements providing access across more than 5,000 healthcare facilities, representing approximately 60% of the institutional GPO

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

COMMACK, NY, June 09, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that REZENOPY™ (naloxone HCl)

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team

Tue, 09 Jun 2026 08:05:00 -0400

Commercial Launch Planned for Mid-July; 5,000+ Healthcare Facilities Reached Through GPO Agreements, Covering ~60% of Institutional GPO Market

U.S. naloxone market totals ~$144 million in annual sales and ~9.8 million units annually, represents significant commercial opportunity for REZENOPY™

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

Thu, 04 Jun 2026 08:00:00 -0400

COMMACK, NY / ACCESS Newswire / June 4, 2026 / SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City.

Narasimhan Mani, President, co-CEO and Interim CFO of Scienture, will deliver a corporate presentation at

SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC

Thu, 04 Jun 2026 08:00:00 -0400

Narasimhan Mani, President, co-CEO and Interim CFO of Scienture, will deliver a corporate presentation at

SCIENTURE receives patent for naloxone nasal spray through 2041

Tue, 02 Jun 2026 08:06:22 -0400

Scienture Holdings Inc. (NASDAQ: SCNX) announced that the U.S. Patent and Trademark Office granted Patent No. 12,622,903 B2 covering its REZENOPY naloxone HCl nasal spray 10 mg, with protection extending through February 5, 2041.

The patent was issued to Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P. Scienture entered into an agreement with Summit in March 2025 for exclusive U.S. commercialization rights to REZENOPY. Under the collaboration terms, Summit will manufacture and supply the product while Scienture handles sales, marketing and distribution.

REZENOPY received FDA approval on April 19, 2024, and delivers 10 mg of naloxone HCl in a single-use

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041